Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 7, 2010, Pages 1312-1329

  Torres, Vicente E ^a   Boletta, Alessandra ^b   Chapman, Arlene ^c   Gattone, Vincent ^d   Pei, York ^e   Qian, Qi ^a   Wallace, Darren P ^f   Weimbs, Thomas ^g   Wüthrich, Rudolf P ^h  

^a Mayo Clinic   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TORONTO GENERAL HOSPITAL   (Canada)

^f UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; DEFOROLIMUS; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NITRIC OXIDE; PROTEIN KINASE B; PROTEIN MTORC1; PROTEIN MTORC2; RAPAMYCIN; TACROLIMUS; TEMSIROLIMUS; TESTOSTERONE; UNCLASSIFIED DRUG; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ACNE; ANEMIA; ANGIOGENESIS; ANGIONEUROTIC EDEMA; ARTHRALGIA; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; DERMATITIS; DIARRHEA; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOTHELIUM CELL; ENZYME ACTIVATION; EYELID EDEMA; FOLLICULITIS; GLOMERULUS; HAMARTOMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INTERSTITIAL PNEUMONIA; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY INJURY; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE CELL; LEG EDEMA; LEUKOPENIA; LYMPHEDEMA; MICROANGIOPATHY; MOUTH ULCER; MUCOSA INFLAMMATION; NEPHROSCLEROSIS; NEPHROTOXICITY; NONHUMAN; PODOCYTE; PROTEINURIA; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SPERMATOGENESIS; SYNTHESIS; TESTOSTERONE BLOOD LEVEL; THROMBOCYTOPENIA; VASOSPASM; WOUND HEALING IMPAIRMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; POLYCYSTIC KIDNEY DISEASES; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; HAMARTOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; POLYCYSTIC KIDNEY DISEASES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 77954770878     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01360210     Document Type: Review

References (205)

1. Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 369: 1287-1301, 2007
2. Roach ES, Gomez MR, Northrup H: Tuberous sclerosis complex consensus conference: Revised clinical diagnostic criteria. J Child Neurol 13: 624-628, 1998
3. European Chromosome 16 Tuberous Sclerosis Consortium: Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75: 1305-1315, 1993
4. The European Polycystic Kidney Disease Consortium: The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. Cell 78: 725, 1994
5. Venkatachalam K, Montell C: TRP channels. Annu Rev Biochem 76: 387-417, 2007
6. Li Y, Corradetti MN, Inoki K, Guan KL: TSC2: Filling the GAP in the mTOR signaling pathway. Trends Biochem Sci 29: 32-38, 2004
7. Brook-Carter PT, Peral B, Ward CJ, Thompson P, Hughes J, Maheshwar MM, Nellist M, Gamble V, Harris PC, Sampson JR: Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease - A contiguous gene syndrome. Nat Genet 8: 328-332, 1994
8. Torres VE, Harris PC: Autosomal dominant polycystic kidney disease: The last 3 years. Kidney Int 76: 149-168, 2009
9. Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell 124: 471-484, 2006
10. Huang J, Manning BD: The TSC1-TSC2 complex: A molecular switchboard controlling cell growth. Biochem J 412: 179-190, 2008
11. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument- Bromage H, Tempst P, Sabatini DM: mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175, 2002
12. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM: Rictor, a novel binding partner of mTOR, defines a rapamycininsensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302, 2004
13. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/ PKB. Mol Cell 22: 159-168, 2006
14. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt/PKB by the RictormTOR complex. Science 307: 1098-1101, 2005
15. Saucedo LJ, Gao X, Chiarelli DA, Li L, Pan D, Edgar BA: Rheb promotes cell growth as a component of the insulin/ TOR signaling network. Nat Cell Biol 5: 566-571, 2003 (Pubitemid 36781092)
16. Hsu YC, Chern JJ, Cai Y, Liu M, Choi KW: Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature 445: 785-788, 2007 (Pubitemid 46279709)
17. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J: Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPaseactivating protein complex toward Rheb. Curr Biol 13: 1259-1268, 2003
18. Ballif BA, Roux PP, Gerber SA, MacKeigan JP, Blenis J, Gygi SP: Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci U S A 102: 667-672, 2005 (Pubitemid 40282723)
19. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC: Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10: 151-162, 2002 (Pubitemid 34876569)
20. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J: Tumorpromoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A 101: 13489-13494, 2004 (Pubitemid 39238430)
21. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP: Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121: 179-193, 2005 (Pubitemid 40546387)
22. Inoki K, Zhu T, Guan KL: TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590, 2003 (Pubitemid 37506046)
23. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL: TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126: 955-968, 2006
24. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG Jr: Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18: 2893-2904, 2004
25. Pearson RB, Dennis PB, Han JW, Williamson NA, Kozma SC, Wettenhall RE, Thomas G: The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. EMBO J 14: 5279-5287, 1995
26. Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD, Kwiatkowski DJ: PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 117: 730-738, 2007 (Pubitemid 46348531)
27. Shah OJ, Wang Z, Hunter T: Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14: 1650-1656, 2004 (Pubitemid 39239362)
28. Shah OJ, Hunter T: Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. Mol Cell Biol 26: 6425-6434, 2006
29. Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC: Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 19: 1773-1778, 2005 (Pubitemid 41126916)
30. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074, 2008
31. Faivre S, Kroemer G, Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671-688, 2006 (Pubitemid 44151605)
32. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J: Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate celltype- specific repression of mRNA translation. Proc Natl Acad Sci U S A 105: 17414-17419, 2008
33. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di CS, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-8030, 2008
34. Molhoek KR, Brautigan DL, Slingluff CL Jr: Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor rapamycin. J Transl Med 3: 39, 2005
35. Inoki K, Corradetti MN, Guan KL: Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37: 19-24, 2005 (Pubitemid 40070934)
36. Rosner M, Hanneder M, Siegel N, Valli A, Fuchs C, Hengstschlager M: The mTOR pathway and its role in human genetic diseases. Mutat Res 659: 284-292, 2008
37. Rosner M, Hengstschlager M: Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: Rapamycin triggers dephosphorylation and delocalization of the mTORC2 components Rictor and sin1. Hum Mol Genet 17: 2934-2948, 2008
38. Hartman TR, Liu D, Zilfou JT, Robb V, Morrison T, Watnick T, Henske EP: The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway. Hum Mol Genet 18: 151-163, 2009
39. Crino PB, Nathanson KL, Henske EP: The tuberous sclerosis complex. N Engl J Med 355: 1345-1356, 2006
40. Kwiatkowski DJ, Manning BD: Tuberous sclerosis: A GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 14: R251-R258, 2005
41. Eng C: PTEN: One gene, many syndromes. Hum Mutat 22: 183-198, 2003
42. Lachlan KL, Lucassen AM, Bunyan D, Temple IK: Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and agerelated penetrance: Results of a clinical study of PTEN mutation carriers. J Med Genet 44: 579-585, 2007 (Pubitemid 47441766)
43. McClatchey AI: Neurofibromatosis. Annu Rev Pathol 2: 191-216, 2007
44. Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL: Regulation of the TSC pathway by LKB1: Evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 18: 1533-1538, 2004
45. Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, Esposito D, Gillette WK, Hopkins RF III, Hartley JL, Furihata M, Oishi S, Zhen W, Burke TR Jr, Linehan WM, Schmidt LS, Zbar B: Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A 103: 15552-15557, 2006
46. Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, Southon E, Patel V, Igarashi P, Alvord WG, Leighty R, Yao M, Bernardo M, Ileva L, Choyke P, Warren MB, Zbar B, Linehan WM, Schmidt LS: Kidney-targeted Birt-Hogg- Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst 100: 140-154, 2008
47. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T: The mTOR pathway is regulated by polycystin- 1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103: 5466-5471, 2006
48. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358: 140-151, 2008
49. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF: The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166: 213-223, 2004
50. The European Polycystic Kidney Disease Consortium: The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. Cell 77: 881-894, 1994
51. Sandford R, Sgotto B, Burn T, Brenner S: The tuberin (TSC2), autosomal dominant polycystic kidney disease (PKD1), and somatostatin type V receptor (SSTR5) genes form a synteny group in the Fugu genome. Genomics 38: 84-86, 1996
52. Bonnet CS, Aldred M, von Ruhland C, Harris R, Sandford R, Cheadle JP: Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis. Hum Mol Genet 18: 2166-2176, 2009
53. Fischer DC, Jacoby U, Pape L, Ward CJ, Kuwertz-Broeking E, Renken C, Nizze H, Querfeld U, Rudolph B, Mueller- Wiefel DE, Bergmann C, Haffner D: Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD). Nephrol Dial Transplant 24: 1819-1827, 2009
54. Cook JA, Oliver K, Mueller RF, Sampson J: A cross sectional study of renal involvement in tuberous sclerosis. J Med Genet 33: 480-484, 1996
55. Weimbs T: Polycystic kidney disease and renal injury repair: Common pathways, fluid flow, and the function of polycystin-1. Am J Physiol Renal Physiol 293: F1423-F1432, 2007
56. Weimbs T: Regulation of mTOR by polycystin-1: Is polycystic kidney disease a case of futile repair? Cell Cycle 5: 2425-2429, 2006
57. Distefano G, Boca M, Rowe I, Wodarczyk C, Ma L, Piontek KB, Germino GG, Pandolfi PP, Boletta A: Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol 29: 2359-2371, 2009
58. Govindarajan B, Mizesko MC, Miller MS, Onda H, Nunnelley M, Casper K, Brat D, Cohen C, Arbiser JL: Tuberous sclerosis-associated neoplasms express activated p42/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth. Clin Cancer Res 9: 3469-3475, 2003
59. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP: Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 279: 40419-40430, 2004
60. Yamaguchi T, Hempson SJ, Reif GA, Hedge AM, Wallace DP: Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 17: 178-187, 2006
61. Guan KL, Figueroa C, Brtva TR, Zhu T, Taylor J, Barber TD, Vojtek AB: Negative regulation of the serine/threonine kinase B-Raf by Akt. J Biol Chem 275: 27354-27359, 2000
62. Wahl PR, Le Hir M, Vogetseder A, Arcaro A, Starke A, Waeckerle-Men Y, Serra AL, Wuthrich RP: Mitotic activation of Akt signaling pathway in Han:SPRD rats with polycystic kidney disease. Nephrology (Carlton) 12: 357-363, 2007
63. DiJoseph JF, Sharma RN, Chang JY: The effect of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation 53: 507-513, 1992
64. Lieberthal W, Fuhro R, Andry CC, Rennke H, Abernathy VE, Koh JS, Valeri R, Levine JS: Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 281: F693-F706, 2001
65. Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W: Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 16: 2063-2072, 2005 (Pubitemid 41716437)
66. Chen JK, Chen J, Neilson EG, Harris RC: Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J Am Soc Nephrol 16: 1384-1391, 2005 (Pubitemid 41716522)
67. Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, Tang MJ: Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 69: 2029-2036, 2006 (Pubitemid 43924267)
68. Brown JH, Bihoreau MT, Hoffmann S, Kranzlin B, Tychinskaya I, Obermuller N, Podlich D, Boehn SN, Kaisaki PJ, Megel N, Danoy P, Copley RR, Broxholme J, Witzgall R, Lathrop M, Gretz N, Gauguier D: Missense mutation in sterile alpha motif of novel protein SamCystin is associated with polycystic kidney disease in (Cy/+) rat. J Am Soc Nephrol 16: 3517-3526, 2005
69. Tao Y, Kim J, Schrier RW, Edelstein CL: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16: 46-51, 2005 (Pubitemid 43073155)
70. Wahl PR, Serra AL, Le HM, Molle KD, Hall MN, Wuthrich RP: Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 21: 598-604, 2006 (Pubitemid 43372904)
71. Zhang T, Wang L, Xiong X, Mao Z, Wang L, Mei C: Mycophenolate mofetil versus rapamycin in Han:SPRD rats with polycystic kidney disease. Biol Res 42: 437-444, 2009
72. Wu M, Wahl PR, Le HM, Wackerle-Men Y, Wuthrich RP, Serra AL: Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 30: 253-259, 2007 (Pubitemid 47076223)
73. Zafar I, Belibi FA, He Z, Edelstein CL: Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant 24: 2349-2353, 2009
74. Brown NE, Murcia NS: Delayed cystogenesis and increased ciliogenesis associated with the re-expression of polaris in Tg737 mutant mice. Kidney Int 63: 1220-1229, 2003
75. Olbrich H, Fliegauf M, Hoefele J, Kispert A, Otto E, Volz A, Wolf MT, Sasmaz G, Trauer U, Reinhardt R, Sudbrak R, Antignac C, Gretz N, Walz G, Schermer B, Benzing T, Hildebrandt F, Omran H: Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis. Nat Genet 34: 455-459, 2003
76. Gattone VH, Sinders RM, Hornberger TA, Robling AG: Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis. Kidney Int 76: 178-182, 2009
77. Reichardt W, Romaker D, Becker A, Buechert M, Walz G, von Elverfeldt D: Monitoring kidney and renal cyst volumes applying MR approaches on a rapamycin treated mouse model of ADPKD. MAGMA 22: 143-149, 2009
78. Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML, Duray P, Merino M, Choyke P, Pavlovich CP, Sharma N, Walther M, Munroe D, Hill R, Maher E, Greenberg C, Lerman MI, Linehan WM, Zbar B, Schmidt LS: Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell 2: 157-164, 2002
79. Hasumi H, Baba M, Hong SB, Hasumi Y, Huang Y, Yao M, Valera VA, Linehan WM, Schmidt LS: Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene 415: 60-67, 2008
80. Shillingford JM, Piontek KB, Germino GG, Weimbs T: Rapamycin ameliorates PKD resulting from conditional inactivation of pkd1. J Am Soc Nephrol 21: 489-497, 2010
81. Spirli C, Okolicsanyi S, Fiorotto R, Fabris L, Cadamuro M, Lecchi S, Tian X, Somlo S, Strazzabosco M: Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. Hepatology 51: 1-11, 2009
82. Zeng LH, Xu L, Gutmann DH, Wong M: Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 63: 444-453, 2008 (Pubitemid 351614710)
83. Qian Q, Du H, King BF, Kumar S, Dean PG, Cosio FG, Torres VE: Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 19: 631-638, 2008 (Pubitemid 351355407)
84. Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C: The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 84: 1492-1499, 2007 (Pubitemid 350294725)
85. Sakaguchi M, Isono M, Isshiki K, Sugimoto T, Koya D, Kashiwagi A: Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun 340: 296-301, 2006 (Pubitemid 41827680)
86. Jain S, Bicknell GR, Whiting PH, Nicholson ML: Rapamycin reduces expression of fibrosis-associated genes in an experimental model of renal ischaemia reperfusion injury. Transplant Proc 33: 556-558, 2001 (Pubitemid 32237513)
87. Yang B, Jain S, Pawluczyk IZ, Imtiaz S, Bowley L, Ashra SY, Nicholson ML: Inflammation and caspase activation in long-term renal ischemia/reperfusion injury and immunosuppression in rats. Kidney Int 68: 2050-2067, 2005 (Pubitemid 43117780)
88. Yang B, Jain S, Ashra SY, Furness PN, Nicholson ML: Apoptosis and caspase-3 in long-term renal ischemia/ reperfusion injury in rats and divergent effects of immunosuppressants. Transplantation 81: 1442-1450, 2006 (Pubitemid 43847156)
89. Damiao MJ, Bertocchi AP, Monteiro RM, Goncalves GM, Cenedeze MA, Feitoza CQ, Marques GD, Giannocco G, Mazzali M, Teixeira VP, Dos Reis MA, Pacheco-Silva A, Camara NO: The effects of rapamycin in the progression of renal fibrosis. Transplant Proc 39: 457-459, 2007
90. Schaefer L, Tsalastra W, Babelova A, Baliova M, Minnerup J, Sorokin L, Grone HJ, Reinhardt DP, Pfeilschifter J, Iozzo RV, Schaefer RM: Decorin-mediated regulation of fibrillin- 1 in the kidney involves the insulin-like growth factor-I receptor and mammalian target of rapamycin. Am J Pathol 170: 301-315, 2007
91. Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, Rama I, Vidal A, Grinyo JM: Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 17: 1395-1404, 2006 (Pubitemid 43673420)
92. Wittmann S, Daniel C, Stief A, Vogelbacher R, Amann K, Hugo C: Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat. Transplantation 87: 1290-1299, 2009
93. Yang Y, Wang J, Qin L, Shou Z, Zhao J, Wang H, Chen Y, Chen J: Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 27: 495-502, 2007 (Pubitemid 47482007)
94. Zdychova J, Kazdova L, Pelikanova T, Lindsley JN, Anderson S, Komers R: Renal activity of Akt kinase in obese Zucker rats. Exp Biol Med (Maywood) 233: 1231-1241, 2008
95. Sataranatarajan K, Mariappan MM, Lee MJ, Feliers D, Choudhury GG, Barnes JL, Kasinath BS: Regulation of elongation phase of mRNA translation in diabetic nephropathy: Amelioration by rapamycin. Am J Pathol 171: 1733-1742, 2007
96. Coombes JD, Mreich E, Liddle C, Rangan GK: Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. Kidney Int 68: 2599-2607, 2005 (Pubitemid 43251006)
97. Das F, Ghosh-Choudhury N, Mahimainathan L, Venkatesan B, Feliers D, Riley DJ, Kasinath BS, Choudhury GG: Raptor-Rictor axis in TGFβ-induced protein synthesis. Cell Signal 20: 409-423, 2008
98. Goncalves GM, Cenedeze MA, Feitoza CQ, de Paula CB, Marques GD, Pinheiro HS, de Paula Antunes Teixeira V, Antônia dos RM, Pacheco-Silva A, Câmara NO: The role of immunosuppressive drugs in aggravating renal ischemia and reperfusion injury. Transplant Proc 39: 417-420, 2007
99. Lui SL, Chan KW, Tsang R, Yung S, Lai KN, Chan TM: Effect of rapamycin on renal ischemia-reperfusion injury in mice. Transpl Int 19: 834-839, 2006 (Pubitemid 44358851)
100. Fuller TF, Freise CE, Serkova N, Niemann CU, Olson JL, Feng S: Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. Transplantation 76: 1594-1599, 2003 (Pubitemid 37549833)
101. Lieberthal W, Fuhro R, Andry C, Patel V, Levine JS: Rapamycin delays but does not prevent recovery from acute renal failure: Role of acquired tubular resistance. Transplantation 82: 17-22, 2006 (Pubitemid 44296972)
102. Rangan GK, Coombes JD: Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis. Nephrol Dial Transplant 22: 2175-2182, 2007 (Pubitemid 47244694)
103. Lui SL, Tsang R, Chan KW, Zhang F, Tam S, Yung S, Chan TM: Rapamycin attenuates the severity of murine adriamycin nephropathy. Am J Nephrol 29: 342-352, 2009
104. Daniel C, Ziswiler R, Frey B, Pfister M, Marti HP: Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative. Exp Nephrol 8: 52-62, 2000 (Pubitemid 30051354)
105. Vollenbroker B, George B, Wolfgart M, Saleem MA, Pavenstadt H, Weide T: mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol 296: F418-F426, 2009
106. Letavernier E, Bruneval P, Vandermeersch S, Perez J, Mandet C, Belair MF, Haymann JP, Legendre C, Baud L: Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 24: 630-638, 2009
107. Naumovic R, Jovovic D, Basta-Jovanovic G, Miloradovic Z, Mihailovic-Stanojevic N, Aleksic T, Jovanovic D: Effects of rapamycin on active Heymann nephritis. Am J Nephrol 27: 379-389, 2007
108. Daniel C, Renders L, Amann K, Schulze-Lohoff E, Hauser IA, Hugo C: Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat. Am J Transplant 5: 2849-2861, 2005
109. Wittmann S, Daniel C, Braun A, Vogelbacher R, Shimizu F, Kawachi H, Hugo C: The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat. Nephron Exp Nephrol 108: e45-e56, 2008
110. Warner LM, Adams LM, Sehgal SN: Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum 37: 289-297, 1994
111. Ramos-Barrón A, Piñera-Haces C, Gómez-Alamillo C, Santiuste- Torcida I, Ruiz JC, Buelta-Carrillo L, Merino R, de Francisco AL, Arias M: Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment. Lupus 16: 775-781, 2007
112. Hochegger K, Jansky GL, Soleiman A, Wolf AM, Tagwerker A, Seger C, Griesmacher A, Mayer G, Rosenkranz AR: Differential effects of rapamycin in anti-GBM glomerulonephritis. J Am Soc Nephrol 19: 1520-1529, 2008
113. Griffin MD, Torres VE, Grande JP, Kumar R: Vascular expression of polycystin. J Am Soc Nephrol 8: 616-626, 1997
114. Torres VE, Cai Y, Chen X, Wu GQ, Geng L, Cleghorn KA, Johnson CM, Somlo S: Vascular expression of polycystin-2. J Am Soc Nephrol 12: 1-9, 2001
115. Ibraghimov-Beskrovnaya O, Dackowski WR, Foggensteiner L, Coleman N, Thiru S, Petry LR, Burn TC, Connors TD, Van RT, Bradley J, Qian F, Onuchic LF, Watnick TJ, Piontek K, Hakim RM, Landes GM, Germino GG, Sandford R, Klinger KW: Polycystin: In vitro synthesis, in vivo tissue expression, and subcellular localization identifies a large membrane-associated protein. Proc Natl Acad Sci U S A 94: 6397-6402, 1997
116. Qian Q, Li M, Cai Y, Ward CJ, Somlo S, Harris PC, Torres VE: Analysis of the polycystins in aortic vascular smooth muscle cells. J Am Soc Nephrol 14: 2280-2287, 2003
117. Morel N, Vandenberg G, Ahrabi AK, Caron N, Desjardins F, Balligand JL, Horie S, Devuyst O: PKD1 haploinsufficiency is associated with altered vascular reactivity and abnormal calcium signaling in the mouse aorta. Pflugers Arch 457: 845-856, 2009
118. Raichlin E, Bae JH, Khalpey Z, Edwards BS, Kremers WK, Clavell AL, Rodeheffer RJ, Frantz RP, Rihal C, Lerman A, Kushwaha SS: Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 116: 2726-2733, 2007
119. Abou Alaiwi WA, Takahashi M, Mell BR, Jones TJ, Ratnam S, Kolb RJ, Nauli SM: Ciliary polycystin-2 is a mechanosensitive calcium channel involved in nitric oxide signaling cascades. Circ Res 104: 860-869, 2009
120. Wang D, Iversen J, Wilcox CS, Strandgaard S: Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 64: 1381-1388, 2003
121. Ritter SA, Baehr G: The arterial supply of the congenital polycystic kidney and its relation to the clinical picture. J Urol 21: 583-592, 1929
122. Chapman AB, Rubinstein D, Hughes R, Stears JC, Earnest MP, Johnson AM, Gabow PA, Kaehny WD: Intracranial aneurysms in autosomal dominant polycystic kidney disease. N Engl J Med 327: 916-920, 1992
123. Turkmen K, Oflaz H, Uslu B, Cimen AO, Elitok A, Kasikcioglu E, Alisir S, Tufan F, Namli S, Uysal M, Ecder T: Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: From impaired tubules to impaired carotid and coronary arteries. Clin J Am Soc Nephrol 3: 986-991, 2008
124. Zeier M, Fehrenbach P, Geberth S, Mohring K, Waldherr R, Ritz E: Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 42: 1259-1265, 1992
125. Schacht FW: Hypertension in cases of polycystic kidney. Arch Intern Med 47: 500-509, 1931
126. Ettinger A, Kahn PC, Wise HM Jr: The importance of selective renal angiography in the diagnosis of polycystic disease. J Urol 102: 156-161, 1969
127. Wei W, Popov V, Walocha JA, Wen J, Bello-Reuss E: Evidence of angiogenesis and microvascular regression in autosomal- dominant polycystic kidney disease kidneys: A corrosion cast study. Kidney Int 70: 1261-1268, 2006
128. Bello-Reuss E, Holubec K, Rajaraman S: Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int 60: 37-45, 2001
129. Martinez-Lemus LA, Hill MA, Meininger GA: The plastic nature of the vascular wall: a continuum of remodeling events contributing to control of arteriolar diameter and structure. Physiology (Bethesda) 24: 45-57, 2009
130. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ: Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 16: 771-780, 2002
131. Tao Y, Kim J, Yin Y, Zafar I, Falk S, He Z, Faubel S, Schrier RW, Edelstein CL: VEGF receptor inhibition slows the progression of polycystic kidney disease. Kidney Int 72: 1358-1366, 2007 (Pubitemid 350126784)
132. Angelo LS, Kurzrock R: Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 13: 2825-2830, 2007 (Pubitemid 46849555)
133. Rzucidlo EM, Martin KA, Powell RJ: Regulation of vascular smooth muscle cell differentiation. J Vasc Surg 45[Suppl A]: A25-A32, 2007
134. Martin KA, Merenick BL, Ding M, Fetalvero KM, Rzucidlo EM, Kozul CD, Brown DJ, Chiu HY, Shyu M, Drapeau BL, Wagner RJ, Powell RJ: Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling. J Biol Chem 282: 36112-36120, 2007
135. Jindra PT, Jin YP, Rozengurt E, Reed EF: HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 180: 2357-2366, 2008
136. Mourani PM, Garl PJ, Wenzlau JM, Carpenter TC, Stenmark KR, Weiser-Evans MC: Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN. Circulation 109: 1299-1306, 2004
137. Tang Z, Wang Y, Fan Y, Zhu Y, Chien S, Wang N: Suppression of c-Cbl tyrosine phosphorylation inhibits neointimal formation in balloon-injured rat arteries. Circulation 118: 764-772, 2008
138. Sousa JE, Costa MA, Abizaid A, Feres F, Seixas AC, Tanajura LF, Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW, Sousa AG: Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimuseluting stents. Circulation 111: 2326-2329, 2005
139. Sinha SS, Pham MX, Vagelos RH, Perlroth MG, Hunt SA, Lee DP, Valantine HA, Yeung AC, Fearon WF: Effect of rapamycin therapy on coronary artery physiology early after cardiac transplantation. Am Heart J 155: 889.e1- e6, 2008
140. Barilli A, Visigalli R, Sala R, Gazzola GC, Parolari A, Tremoli E, Bonomini S, Simon A, Closs EI, Dall'Asta V, Bussolati O: In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Cardiovasc Res 78: 563-571, 2008
141. Dada S, Demartines N, Dormond O: mTORC2 regulates PGE2-mediated endothelial cell survival and migration. Biochem Biophys Res Commun 372: 875-879, 2008
142. Li W, Petrimpol M, Molle KD, Hall MN, Battegay EJ, Humar R: Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2. Circ Res 100: 79-87, 2007 (Pubitemid 46066776)
143. Xue Q, Nagy JA, Manseau EJ, Phung TL, Dvorak HF, Benjamin LE: Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. Arterioscler Thromb Vasc Biol 29: 1172-1178, 2009
144. Dormond O, Madsen JC, Briscoe DM: The effects of mTORAkt interactions on anti-apoptotic signaling in vascular endothelial cells. J Biol Chem 282: 23679-23686, 2007 (Pubitemid 47311969)
145. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC: Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399: 597-601, 1999
146. Ackah E, Yu J, Zoellner S, Iwakiri Y, Skurk C, Shibata R, Ouchi N, Easton RM, Galasso G, Birnbaum MJ, Walsh K, Sessa WC: Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J Clin Invest 115: 2119-2127, 2005
147. Bavry AA, Chiu JH, Jefferson BK, Karha J, Bhatt DL, Ellis SG, Whitlow PL: Development of coronary aneurysm after drug-eluting stent implantation. Ann Intern Med 146: 230-232, 2007 (Pubitemid 351650642)
148. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293: 2126-2130, 2005
149. Lee SE, John SH, Lim JH, Rhew JY: Very late stent thrombosis associated with multiple stent fractures and peristent aneurysm formation after sirolimus-eluting stent implantation. Circ J 72: 1201-1204, 2008
150. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, Mintz GS, Nagata S: Incomplete neointimal coverage of sirolimus-eluting stents: Angioscopic findings. J Am Coll Cardiol 47: 2108-2111, 2006
151. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 8: 128-135, 2002
152. Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM: Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc Natl Acad Sci U S A 105: 13544-13549, 2008
153. Amura CR, Brodsky KS, Groff R, Gattone VH, Voelkel NF, Doctor RB: VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice. Am J Physiol Cell Physiol 293: C419-C428, 2007
154. Grath-Morrow S, Cho C, Molls R, Burne-Taney M, Haas M, Hicklin DJ, Tuder R, Rabb H: VEGF receptor 2 blockade leads to renal cyst formation in mice. Kidney Int 69: 1741-1748, 2006 (Pubitemid 43739200)
155. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ: Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 12: 1448-1457, 2001 (Pubitemid 32666327)
156. Kang DH, Johnson RJ: Vascular endothelial growth factor: A new player in the pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens 12: 43-49, 2003 (Pubitemid 36092314)
157. Fine LG, Norman JT: Chronic hypoxia as a mechanism of progression of chronic kidney diseases: From hypothesis to novel therapeutics. Kidney Int 74: 867-872, 2008
158. Reis F, Parada B, Teixeira de Lemos, Garrido P, Dias A, Piloto N, Baptista S, Sereno J, Eufrásio P, Costa E, Rocha- Pereira P, Santos-Silva A, Figueiredo A, Mota A, Teixeira F: Hypertension induced by immunosuppressive drugs: A comparative analysis between sirolimus and cyclosporine. Transplant Proc 41: 868-873, 2009
159. Gurevich F, Perazella MA: Renal effects of anti-angiogenesis therapy: Update for the internist. Am J Med 122: 322-328, 2009
160. Augustine JJ, Bodziak KA, Hricik DE: Use of sirolimus in solid organ transplantation. Drugs 67: 369-391, 2007 (Pubitemid 46425551)
161. Dunn C, Croom KF: Everolimus: A review of its use in renal and cardiac transplantation. Drugs 66: 547-570, 2006
162. Flechner SM: Sirolimus in kidney transplantation indications and practical guidelines: De novo sirolimus-based therapy without calcineurin inhibitors. Transplantation 87[Suppl 8]: S1-S6, 2009
163. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, Margreiter R, Hugo C, Grinyo JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357: 2562-2575, 2007
164. Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR, Gloor JM, Cosio FG, Lund WJ, Kremers WK, Nyberg SL, Ishitani MB, Prieto M, Velosa JA: Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 6: 514-522, 2006
165. Kasiske BL, de Mattos A, Flechner SM, Gallon L, Meier- Kriesche HU, Weir MR, Wilkinson A: Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 8: 1384-1392, 2008
166. Hoogeveen RC, Ballantyne CM, Pownall HJ, Opekun AR, Hachey DL, Jaffe JS, Oppermann S, Kahan BD, Morrisett JD: Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. Transplantation 72: 1244-1250, 2001 (Pubitemid 33026603)
167. Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J: Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. Atherosclerosis 198: 39-48, 2008 (Pubitemid 351406366)
168. Blum CB: Effects of sirolimus on lipids in renal allograft recipients: An analysis using the Framingham risk model. Am J Transplant 2: 551-559, 2002
169. Chueh S-C, Kahan BD: Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: Incidence, risk factors, progression, and prognosis. Transplantation 76: 375-382, 2003
170. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA: Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence. Transplantation 82: 1153-1162, 2006 (Pubitemid 44748017)
171. Wali RK, Weir MR: Chronic allograft dysfunction: Can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function? Curr Opin Organ Transplant 13: 614-621, 2008
172. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; for the Sirolimus CONVERT Trial Study Group: Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87: 233-242, 2009
173. Ruiz JC, Campistol JM, Sanchez-Fructuoso A, Rivera C, Oliver J, Ramos D, Campos B, Arias M, Diekmann F: Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 21: 3252-3257, 2006
174. Aliabadi D, Kammerstatter G, Seebacher G, Rodler S, Wolner E, Grimm M, Pohanka E, Zuckermann A: Development of proteinuria after switch to sirolimus based immunosuppression in long term cardiac transplant patients. Am J Transplant 8: 854-861, 2008 (Pubitemid 351347752)
175. Stephany BR, Boumitri M, Budev M, Alao B, Poggio ED: Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease. J Heart Lung Transplant 28: 564-571, 2009
176. Mreich E, Coombes JD, Rangan GK: Sirolimus does not reduce receptor-mediated endocytosis of albumin in proximal tubule cells. Transplantation 83: 105-107, 2007 (Pubitemid 46104988)
177. Letavernier E, Pe'raldi M-N, Pariente A, Morelon E, Legendre C: Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 80: 1198-1203, 2005
178. Letavernier E, Legendre C: mToR inhibitors-induced proteinuria: Mechanisms, significance, and management. Transplant Rev (Orlando) 22: 125-130, 2008 (Pubitemid 351372914)
179. van den Akker JM, Wetzels JF, Hoitsma AJ: Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int 70: 1355-1357, 2006 (Pubitemid 44435189)
180. Lebranchu Y, Etienne I, Topance O, Westeel PF, Legendre C, de Ligny BH, Le Meur Y, Moulin B, Touchard G, Deteix P, Villemain F, Le Pogamp P, Noel C, Idier I: Preliminary results of a randomized trial comparing sirolimus (SRL) vs cyclosporine (CsA) in 150 transplant recipients receiving a cadaveric renal graft. Transplantation 78: 463, 2004
181. Stephany BR, Augustine JJ, Krishnamurthi V, Goldfarb DA, Flechner SM, Braun WE, Hricik DE, Dennis VW, Poggio ED: Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation 82: 368-374, 2006
182. Buchler M, Caillard S, Barbier S, Thervet E, Toupance O, Mazouz H, Hurault de Ligny B, Le Meur Y, Thierry A, Villemain F, Heng AE, Moulin B, Morin MP, Noel C, Lebranchu Y: Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 7: 2522-2531, 2007
183. Diekmann F, Gutierrez-Dalmau A, Lopez S, Cofan F, Esforzado N, Ricart MJ, Rossich E, Saval N, Torregrosa JV, Oppenheimer F, Campistol JM: Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: Comparison of two CNI-free protocols. Nephrol Dial Transplant 22: 2316-2321, 2007
184. Neau-Cransac M, Moreau K, Deminiere C, Merville P, Saric J: Decrease in sirolimus-induced proteinuria after switch to everolimus in a liver transplant recipient with diabetic nephropathy. Transpl Int 22: 586-587, 2009
185. Letavernier E, Bruneval P, Mandet C, Van Huyen JP, Peraldi MN, Helal I, Noel LH, Legendre C: High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2: 326-333, 2007
186. Fervenza FC, Fitzpatrick PM, Mertz J, Erickson SB, Liggett S, Popham S, Wochos DN, Synhavsky A, Hippler S, Larson TS, Bagniewski SM, Velosa JA: Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 19: 1288-1292, 2004
187. Rangan GK: Sirolimus-associated proteinuria and renal dysfunction. Drug Saf 29: 1153-1161, 2006
188. Tumlin JA, Miller D, Near M, Selvaraj S, Hennigar R, Guasch A: A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 1: 109-116, 2006
189. Senior PA, Paty BW, Cockfield SM, Ryan EA, Shapiro AM: Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 5: 2318-2323, 2005
190. Chapman AB, Johnson AM, Gabow PA, Schrier RW: Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J AmSoc Nephrol 5: 1349-1354, 1994
191. Sharp C, Johnson A, Gabow P: Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 9: 1908-1914, 1998
192. Torres VE: Hypertension, proteinuria, and progression of autosomal dominant polycystic kidney disease: Where do we go from here? Am J Kidney Dis 35: 547-550, 2000
193. Serra AL, Kistler AD, Poster D, Krauer F, Senn O, Raina S, Pavik I, Rentsch K, Regeniter A, Weishaupt D, Wüthrich RP: Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 24: 3334-3342, 2009
194. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr., Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP: Volume progression in polycystic kidney disease. N Engl J Med 354: 2122-2130, 2006
195. Kistler AD, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, Binet I, Spanaus K, Wuthrich RP, Serra AL: Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 75: 235-241, 2009
196. Franz KA, Reubi FC: Rate of functional deterioration in polycystic kidney disease. Kidney Int 23: 526-529, 1983
197. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ: Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med 146: 77-86, 2007
198. Serra AL, Kistler AD, Poster D, Struker M, Wuthrich RP, Weishaupt D, Tschirch F: Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrol 8: 13, 2007
199. Walz G: Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): Is there light at the end of the tunnel? Nephrol Dial Transplant 21: 1752-1757, 2006
200. Soliman AR, Ismail E, Zamil S, Lotfy A: Sirolimus therapy for patients with adult polycystic kidney disease: A pilot study. Transplant Proc 41: 3639-3641, 2009
201. Stallone G, Infante B, Grandaliano G, Gesualdo L: Management of side effects of sirolimus therapy. Transplantation 87[Suppl 8]: S23-S26, 2009
202. Sirolimus (Rapamune®) for autosomal dominant polycystic kidney disease (ADPKD), Bethesda, MD, National Institutes of Health, 2008. Available online at http://clinicaltrials. gov/ct2/show/NCT00346918. Accessed December 17, 2008
203. Sirolimus treatment in patients with autosomal dominant polycystic kidney disease: Renal efficacy and safety (SIRENA), Bethesda, MD, National Institutes of Health, 2007. Available online at http://clinicaltrials.gov/ct2/show/ NCT00491517. Accessed December 18, 2009
204. Pilot study of rapamycin as treatment for autosomal dominant polycystic kidney disease (ADPKD), Bethesda, MD, National Institutes of Health, 2006. Available online at http://clinicaltrials.gov/ct2/show/NCT00286156. Accessed November 18, 2009
205. Efficacy, safety and tolerability of everolimus in preventing end-stage renal disease in patients with autosomal dominant polycystic kidney disease, Bethesda, MD, National Institutes of Health, 2008. Available online at http://clinicaltrials.gov/ ct2/show/NCT00414440?term=NCT00414440. Accessed November 18, 2009